Saturday (03.10.2026)
08:30 – 11:00
Room: Großer Saal
Scientific Session EHA-LYG/GHSG Joint Session: EHA Clinical Practice Guidelines in Lymphoid Malignancies - From Recommendations to Patient Care
- Igor Aurer
- Bastian von Tresckow
-
10:10–10:30
New Therapeutic Concepts and Horizons in Lymphoma
- Catherine Diefenbach
-
08:30–09:40
Part I: ctDNA for MRD
- Maria Cristina Pirosa
-
09:40–10:00
intermission
-
10:00–11:00
Part II: ctDNA for Genotyping and Classifying HL
- Sven Borchmann
-
08:30–08:55
Early-Stages and Indvidualization
- George Mikhaeel
- Michael Oertel
-
08:55–09:20
Advanced Stages/Recurrence
- Christian Baues
- Mario Levis
-
09:20–09:45
Older age
- Ingrid Glimelius
- Lena Specht
-
09:45–10:10
NLPHL
- Michael Binkley
- Dennis Eichenauer
-
10:10–11:00
Round Table Discussion: How low can we go with dose and fields?
- Berthe Aleman
- David Cutter
- Bouthaina Dabaja
- David Hodgson
- Richard Hoppe
- Brandon Imber
- Umberto Ricardi
11:30 – 13:00
Room: Großer Saal
Satellite Symposium (by Miltenyi Biomedicine) Moving Targets: Rethinking Cellular Therapy Delivery in Aggressive B-Cell Lymphomas
-
11:30–11:35
Opening and Framing
- Bastian von Tresckow
-
11:35–11:55
R/R DLBCL Treatment Landscape
- Bastian von Tresckow
-
11:55–12:10
Difficult-to-Treat Patients in R/R DLBCL
- Igor Aurer
-
12:10–12:25
CAR-T Delivery and Treatment Timing: Clinical Challenges and Opportunities
- Bastian von Tresckow
-
12:25–12:40
Future Directions in Cellular Therapy
- Anna Sureda
-
12:40–13:00
Panel Discussion and Q&A
13:15 – 14:45
Room: Großer Saal
Scientific Session Early Stages
- Catherine Diefenbach
- Hans Theodor Eich
-
13:15–13:35
Personalized RTx: Focus on RTx Techniques and Late Effect Prediction Models
- David Cutter
-
13:35–13:55
Just PD1-Inhibition? Early Insights from the GHSG INDIE Trial
- Paul J. Bröckelmann
-
13:55–14:15
Debate: Should Novel Agents Be Integrated Into the Frontline Treatment of Early Stage Low Risk HL Patients?
- Graham Collins
- Catherine Diefenbach
15:00 – 16:30
Room: Großer Saal
Satellite Symposium (by Bristol Myers Squibb) Raising the bar in cHL: From frontline treatment to long-term impact
- Peter Borchmann
- Sharon Castellino
- Alex Herrera
-
15:00–15:05
Welcome and introduction
- Peter Borchmann
-
15:05–15:10
The current treatment landscape and challenges in cHL
- Peter Borchmann
-
15:10–15:30
Current and emerging frontline treatment strategies in adult and elderly patients with cHL
- Alex Herrera
-
15:30–15:50
N-AVD vs BrECADD in advanced stage frontline cHL
- Peter Borchmann
- Sharon Castellino
- Alex Herrera
-
15:50–16:10
Current and emerging frontline and R/R treatment strategies in pediatric patients with cHL
- Sharon Castellino
-
16:10–16:25
Panel Q&A session and discussion
- Peter Borchmann
-
16:25–16:30
Summary and close
- Peter Borchmann
17:00 – 18:30
Room: Großer Saal
Main Program Opening Ceremony with Keynote Lecture & Awards
18:30 – 20:00
Room: Foyer (Ground Floor)
Main Program Poster Session & Welcome Reception
-
Project Pitch & Collaboration Plaza
- Stephen Ansell
- Andrew Evens
- Justin Ferdinandus
- Jonathan Friedberg
- Alex Herrera
- Wouter Plattel
-
Early Stages
- Christian Baues
- Catherine Diefenbach
-
HL in Children & Adolescents
- Christine Mauz-Körholz
- Joachim Yahalom
-
Biology & Pathology
- Wolfram Klapper
- Sirpa Leppä
-
Living Beyond Lymphoma
- Karolin Behringer
- John Radford
-
Advanced Stages
- Bastian von Tresckow
- Josée Zijlstra
-
Resource Constrained Settings
- Otavio Baiocchi
- Lena Specht
-
NLPHL
- Dennis Eichenauer
-
Relapsed & Refractory HL
- Herve Ghesquieres
- Pier Luigi Zinzani
ISHL14 Final Program
Save the date
ISHL14: Program at a Glance
Archive
You can explore the ISHL13 program to get an impression of the broad spectrum and diversity of the congress.